| Ticker: ENML | 15 Kimball Avenue | |
| Exchange: NASDAQ-National Market | Yonkers, New York 10704 | |
| Industry: Manufacturing | (914) 237-1308 |
| Type of Shares: | Common Shares | Filing Date: | 6/21/96 | |
| U.S. Shares: | 1,700,000 | Offer Date: | 10/24/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $7.00 - $9.00 | |
| Primary Shares: | 1,700,000 | Offer Price: | $7.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.49 | |
| Offering Amount: | $13,600,000 | Selling: | $0.27 | |
| Expenses: | $600,000 | Reallowance: | $0.10 | |
| Shares Out After: | 6,900,378 |
| Manager | Tier | Phone |
| Rodman & Renshaw, Inc. | Lead Manager | (312) 977-7824 |
| GKN Securities | Co-manager | (212) 509-3800 |
| Auditor: BDO Seidman | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $3.12 |
| Net Income: | -$1.06 | -$1.02 | -$0.46 | Liabilities: | $2.25 |
| EPS: | -$0.20 | -$0.19 | Equity: | $0.88 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company plans to develop and market over-the-counter oral hygiene products intended to prevent cavities. Enamelon toothpaste is designed to prevent cavities by strengthening tooth enamel. The products are based on the active ingredient sodium fluoride in a formulation that enhances tooth "remineralization," whereby minerals, such as calcium and phosphate, are reintroduced into the tooth enamel. With toothpaste product development activities nearing completion, the Company plans to introduce an all-family toothpaste into test markets, consisting of approximately 5% of the United States households, in the early part of 1997. The Company currently expects to begin a nationwide roll-out of its toothpaste product in the first half of 1998. The worldwide toothpaste market is estimated to exceed $5 billion in annual retail sales. Annual toothpaste sales in the United States are expected to be $1.7 billion in 1996 and are projected to reach $2 billion by the turn of the century. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for marketing and research, purchases of equipment, working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.